Haemostatic effects of iloprost in patients with lower limb ischemia.
Haemostatic effects of iloprost in patients with lower limb ischemia.
复制标题
伊洛前列素对下肢缺血患者的止血作用。
作者：
A. Trifiletti;R. Scamardi;Pizzoleo Ma;A. Nevoso;S. Soraci;S. Bartolone;L. Bagnato;N. Barbera
本研究的目的是研究前列环素的稳定类似物伊洛前列素在外周动脉疾病患者中的止血作用。对13例肢体闭塞性动脉病患者的血浆血栓调节蛋白(TM)、β-凝血球蛋白(β-TG)、D-二聚体(DD)和纤溶酶原激活物抑制物(PAI-1)进行了检测，并与10例健康志愿者进行了比较。在血管病变患者中，所有参数均显著升高。这些止血评估是在伊洛前列素治疗4周后进行的，最高剂量为2 ng/kg/min，每天输注6小时。在治疗过程中和治疗结束时，记录临床改善。治疗结束时，患者的血浆β-甘油三酯和DD水平也显著下降。这些数据提示，伊洛前列素能改善临床症状，可能在一定程度上降低了患者的血小板活化和纤维蛋白转换率。
The aim of this study was to investigate the haemostatic effects of iloprost, a stable analogue of prostacyclin, in patients with peripheral arterial disease. In a group of 13 patients with obliterative arteriopathies of the lower limbs the plasma levels of thrombomodulin (TM), betathromboglobulin (beta-TG), D-dimer (DD) and plasminogen activator-inhibitor (pAI-1) were measured, and compared to the values obtained from 10 healthy volunteers. All the parameters were found to be significantly higher in vasculopathic patients. These haemostatic evaluations were carried out after 4 weeks of treatment with iloprost up to 2 ng/kg/min, 6 hours infusion per day. During and at the end of treatment a clinical improvement was recorded. The patients also showed a significant decrease in plasma beta-TG and DD at the end of treatment. These data suggest that iloprost exerts clinical improvement, in who may have a part the decrease of platelet activation and of fibrin turnover.